Millennium Pharmaceuticals Limited

Pharma-cycle, LLC

Other

The Feinstein Institute for Medical Research

Amgen British Columbia Inc.

Oneighty°c Technologies Corporation

Critical Therapeutics, Inc.

Medimmune Limited

Cornerstone Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

Theresa O'Keefe

Walter Newman

Shixin Qin

Gregory J LaRosa

S Tarran Jones

Christopher Horvath

Siobhan H O'Brien

Paul D Ponath

Robert A Obar

James T Mullowney, Jr

John Stephen Babcook

Edward Alvin Greenfield

Helen Alison Frank

Samuel S Nam

Herren Wu

Changshou Gao

Anthony Coyle

Peter Kiener

Ling-Ling An

Su-Yau Mao

Jane Tian

Peter Luciano

Alice A McDonald

Alice Mcdonald

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Anti-GCC antibody molecules and related compositions and methods

An assembly and method for processing human waste includes providing a supporting base having an opening within which a waste reservoir is affixed. The assembly may be installed on or below a rim of a toilet bowl. Solidification and pathogen killing materials are provided. The materials are deposited in the reservoir either prior to or upon accumulation of waste in the reservoir. The reservoir with the solidified waste is then sealed and transported to a collection facility.

System and method for disposal of mutagen waste

A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device. The defined surrogate protein having the predetermined sequence is subjected to sterilization, deimmunization, or disinfection. The effectiveness of the sterilization deimmunization, or disinfection is rapidly determined by determining if the defined surrogate protein has been destroyed.

Method for rapidly determining effective sterilization, deimmunization, and/or disinfection

Method for rapidly determining effective sterilization , deimmunization, and/or disinfection

Waste containing a cytotoxic chemotherapy drug is collected in a container and contacted with a solidification material to form a solidified waste. The solidification material includes a mixture of an organic polymer and a Portland cement clinker. The organic polymer facilitating dispersal of the Portland cement clinker upon contacting said waste with the solidification material, wherein a volume of the solidified waste forms a stable matrix. The solidified waste is sealed within the container.

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Humanized anti-CCR2 antibodies and methods of use therefor

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Anti-GCC antibody molecules and methods for use of same

A method for using a mixture of an organic polymer combined with an inorganic polymer is provided. When the mixture is combined with a liquid material, such as a urine from a patient that is contaminated with a dangerous cytotoxic drug, a multi-step process occurs that sequester the dangers. The combined material forms a stable matrix in which the cytotoxic chemotherapy drug is destroyed. Due to the combination of polymers, the multi-step process will occur without any mechanical mixing or stirring, as the organic polymer facilitates dispersal of the inorganic polymer through-out the combined material.

The present invention is based, in part, on our discovery of a way to configure expression cassettes so that the expression of a selectable marker protein, which is critical for the growth or survival of a cell, also results in the expression of a protein of interest in a biological cell. Accordingly, in one aspect, the invention features a genetically modified cell (e.g., a bacterial cell) that includes a chromosomally integrated or cytoplasmic expression cassette that includes a first nucleic acid sequence encoding a protein of interest and a second nucleic acid sequence encoding a selectable marker protein. The regulatory sequence (e.g., the sequence encoding a functional promoter) that drives expression of the required selectable marker protein also drives expression of the protein of interest. For that reason, we may refer to their expression as being 'linked' or 'functionally couple.'

Genetically modified biological cells

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

Monoclonal antibodies against HMGB1

Growing community of inventors

Waltham, MA, United States of America

Theresa O'Keefe